| Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with α-, β-, and Auger electron–emitting radionuclides M Boyd, SC Ross, J Dorrens, NE Fullerton, KW Tan, MR Zalutsky, ... Journal of nuclear medicine 47 (6), 1007-1015, 2006 | 210 | 2006 |
| Feasibility of Dosimetry-Based High-Dose 131I-Meta-Iodobenzylguanidine with Topotecan as a Radiosensitizer in Children with Metastatic Neuroblastoma MN Gaze, YC Chang, GD Flux, RJ Mairs, FH Saran, ST Meller Cancer biotherapy & radiopharmaceuticals 20 (2), 195-199, 2005 | 165 | 2005 |
| The effect of cytotoxic therapy on saliva and oral flora BE Main, KC Calman, MM Ferguson, SB Kaye, TW MacFarlane, RJ Mairs, ... Oral Surgery, Oral Medicine, Oral Pathology 58 (5), 545-548, 1984 | 118 | 1984 |
| The role of copper in disulfiram-induced toxicity and radiosensitization of cancer cells C Rae, M Tesson, JW Babich, M Boyd, A Sorensen, RJ Mairs Journal of Nuclear Medicine 54 (6), 953-960, 2013 | 108 | 2013 |
| Noradrenaline transporter gene transfer for radiation cell kill by 131I meta-iodobenzylguanidine M Boyd, SH Cunningham, MM Brown, RJ Mairs, TE Wheldon Gene therapy 6 (6), 1147-1152, 1999 | 100 | 1999 |
| Localized irradiation of cell membrane by Auger electrons is cytotoxic through oxidative stress-mediated nontargeted effects S Paillas, R Ladjohounlou, C Lozza, A Pichard, V Boudousq, M Jarlier, ... Antioxidants & redox signaling 25 (8), 467-484, 2016 | 94 | 2016 |
| Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution JA Barrett, JL Joyal, SM Hillier, KP Maresca, FJ Femia, JF Kronauge, ... Cancer biotherapy & radiopharmaceuticals 25 (3), 299-308, 2010 | 87 | 2010 |
| Experimental targeted radioiodide therapy following transfection of the sodium iodide symporter gene: effect on clonogenicity in both two-and three-dimensional models S Carlin, SH Cunningham, M Boyd, AG McCluskey, RJ Mairs Cancer gene therapy 7 (12), 1529-1536, 2000 | 82 | 2000 |
| Microsatellite analysis for determination of the mutagenicity of extremely low-frequency electromagnetic fields and ionising radiation in vitro RJ Mairs, K Hughes, S Fitzsimmons, KM Prise, A Livingstone, L Wilson, ... Mutation Research/Genetic Toxicology and Environmental Mutagenesis 626 (1-2 …, 2007 | 74 | 2007 |
| Development of a Real-Time Polymerase Chain Reaction Assay for Prediction of the Uptake of Meta-[131I]iodobenzylguanidine by Neuroblastoma Tumors S Carlin, RJ Mairs, AG McCluskey, DA Tweddle, A Sprigg, C Estlin, ... Clinical cancer research 9 (9), 3338-3344, 2003 | 74 | 2003 |
| An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation‐mediated bystander effects M Boyd, RJ Mairs, WN Keith, SC Ross, P Welsh, G Akabani, J Owens, ... The Journal of Gene Medicine: A cross‐disciplinary journal for research on …, 2004 | 71 | 2004 |
| Sodium-iodide symporter (NIS)-mediated accumulation of [211At] astatide in NIS-transfected human cancer cells S Carlin, RJ Mairs, P Welsh, MR Zalutsky Nuclear medicine and biology 29 (7), 729-739, 2002 | 69 | 2002 |
| 131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes MN Gaze, RJ Mairs, SM Boyack, TE Wheldon, A Barrett British journal of cancer 66 (6), 1048-1052, 1992 | 68 | 1992 |
| Prediction of accumulation of 131I-labelled meta-iodobenzylguanidine in neuroblastoma cell lines by means of reverse transcription and polymerase chain reaction RJ Mairs, A Livingstone, MN Gaze, TE Wheldon, A Barrett British journal of cancer 70 (1), 97-101, 1994 | 67 | 1994 |
| An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma DL Nile, C Rae, IJ Hyndman, MN Gaze, RJ Mairs BMC cancer 16, 1-13, 2016 | 65 | 2016 |
| Preclinical Evaluation of an 131I-Labeled Benzamide for Targeted Radiotherapy of Metastatic Melanoma JL Joyal, JA Barrett, JC Marquis, J Chen, SM Hillier, KP Maresca, M Boyd, ... Cancer research 70 (10), 4045-4053, 2010 | 58 | 2010 |
| Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions SH Cunningham, RJ Mairs, TE Wheldon, PC Welsh, G Vaidyanathan, ... British journal of cancer 77 (12), 2061-2068, 1998 | 58 | 1998 |
| Radiation quality‐dependent bystander effects elicited by targeted radionuclides M Boyd, A Sorensen, AG McCluskey, RJ Mairs Journal of Pharmacy and Pharmacology 60 (8), 951-958, 2008 | 56 | 2008 |
| [131I]meta-Iodobenzylguanidine and Topotecan Combination Treatment of Tumors Expressing the Noradrenaline Transporter AG McCluskey, M Boyd, SC Ross, E Cosimo, AM Clark, WJ Angerson, ... Clinical cancer research 11 (21), 7929-7937, 2005 | 56 | 2005 |
| Transfectant mosaic spheroids: a new model for evaluation of tumour cell killing in targeted radiotherapy and experimental gene therapy M Boyd, SC Mairs, K Stevenson, A Livingstone, AM Clark, SC Ross, ... The Journal of Gene Medicine: A cross‐disciplinary journal for research on …, 2002 | 55 | 2002 |
